Genervon Biopharmaceuticals LLC

Release Summary

The GM604 ALS Phase 2A trial data showed favorable shifts in ALS biomarkers and improved clinical and functional measures suggesting a tentative tripartate mechanism of action (MOA), prolonging motor

Genervon Biopharmaceuticals LLC